Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer

Journal of Urology

Volumn 164, Issue 6, 2000, Pages 1992-1995

  Palmberg, C ^a   Koivisto, P ^a   Kakkola, L ^a   Tammela, T L J ^a   Kallioniemi, O P ^a   Visakorpi, T ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Endocrinology; Hormones; Prostate; Therapeutics

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; DRUG RESPONSE; GENE AMPLIFICATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEPTOR GENE; TREATMENT OUTCOME;

EID: 0033767930     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66935-2     Document Type: Article

References (28)

1. Carcinoma of the prostate. Hormonal therapy
2. Hormone refractory disease
3. PSA decline is an independent prognostic marker in hormonally treated prostate cancer
4. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer
5. Combination therapy in stage C and D prostatic cancer: Rationale and five year clinical experience
6. Combined androgen blockade for the treatment of metastatic cancer of the prostate
7. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
8. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
9. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group
10. Benefits of combination therapy with flutamide in patients relapsing after castration
11. Adrenal androgen blockade in relapsed prostate cancer
12. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
13. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
14. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
15. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade
16. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization
17. Experience with flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy
18. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer
19. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction
20. Identification of bone marrow micrometastases in patients with prostate cancer
21. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
22. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
23. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase